+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 16 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a new bevacizumab drug made by Mabscale, LLC, compared to Avastin, both combined with paclitaxel and carboplatin, for treating adults with advanced or inoperable non-squamous non-small cell lung cancer NSCLC. This phase III trial aims to show that the new bevacizumab works as well and is as safe as Avastin. The study also looks at how the drug is processed in the body. Participants are randomly assigned to one of two groups. One group receives the Mabscale bevacizumab with paclitaxel and carboplatin, and the other gets Avastin with the same chemotherapy drugs. Treatment cycles last about three weeks, with up to six cycles initially. After that, eligible patients continue with bevacizumab alone every three weeks. The study is double-blind, so neither patients nor researchers know who receives which bevacizumab. During the study, patients will undergo regular assessments including tumor measurements and blood tests. Researchers measure the tumor response at 18 weeks and track progression-free and overall survival at 18 and 42 weeks. The duration of response is also evaluated up to 48 weeks. Safety and side effects are closely monitored throughout the trial, which started in 2023 and will continue until 2027. Participants are followed closely to assess the treatments impact and safety.

Age: 18Years +All GendersPhase 3
28 locations
O

Actively Recruiting

Researchers are studying the physical impact of Multiple Sclerosis MS from the patients perspective while providing continued access to the drug ocrelizumab. This extension study evaluates the safety and tolerability of ocrelizumab in patients previously enrolled in certain parent studies who no longer have local access to the treatment. The study is open-label and multicenter, sponsored by Hoffmann-La Roche. Participants will receive ocrelizumab at approved doses of either 600 mg via intravenous infusion or 920 mg via subcutaneous injection, following the schedule from their original parent study. Treatment will continue until the medication becomes locally available, an unacceptable safety concern arises, the participant dies, or withdraws consent. During the study, participants will be monitored for changes in physical function using patient-reported outcome measures over up to five years. Researchers will also track access to ocrelizumab, serious adverse events, adverse events leading to discontinuation, and adverse events of special interest. The study will last up to five years, with ongoing safety and tolerability assessments throughout the treatment period.

Age: 18Years +All GendersPhase 3
56 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the immune response, side effects, and safety of a vaccine called GNG-DE compared to a reference vaccine for preventing meningococcal infections. This phase 3 trial is conducted by NPO Petrovax and involves healthy volunteers aged 3 to 55 years. The study is divided into three stages to include adults, adolescents, and children sequentially, with each stage beginning after safety review of the previous stage. Participants are randomly assigned to one of two groups to receive either GNG-DE or the reference vaccine Menactra, both given as 0.5 mL injections into the muscle of the upper arm. The study starts with adults aged 18 to 55 years, then moves to adolescents aged 11 to 17 years, and finally to children aged 3 to 10 years. Each group includes 80 participants, and the dosing and administration are consistent across all age groups. Throughout the study, volunteers undergo screening before enrollment and attend scheduled visits for safety and immune response assessments. The main outcome measured is the primary immune response 29 days after vaccination. Additional immune markers and safety data are also collected. Participants will be monitored closely to track any reactions or side effects, with all procedures conducted under medical supervision until the study ends in late 2025.

Age: 3Years - 55YearsAll GendersPhase 3
17 locations
O

Actively Recruiting

Researchers are studying adult patients with Neurofibromatosis type 1 NF1 in Russia to evaluate clinical and patient-reported outcomes in routine care settings. This observational, open-label, single-arm, multi-center cohort study focuses on adults diagnosed with NF1 and associated plexiform neurofibromas PN. Participants are adults aged 18 years or older with confirmed NF1 and PN diagnosis verified by clinical assessment, ultrasound imaging, MRI, or biopsy. The study includes patients with existing PN-associated symptoms who are either newly diagnosed or have PN without prior MEK-inhibitor therapy. No investigational drugs are given, as this is a non-interventional study observing routine care. During the study, participants provide data at their initial visit, including demographics, clinical history, PN characteristics, comorbidities, disability degree, and prior examinations. Researchers collect information on hospitalizations and disease progression over time. The primary outcomes include age at inclusion and diagnosis, body measurements, symptom duration, and disability changes. Participants are followed according to routine care until study completion in 2028.

All AgesAll Genders
16 locations
P

Actively Recruiting

Researchers are evaluating Raphamin in adults aged 18 to 64 years who have acute bronchitis symptoms lasting less than 72 hours. This randomized, double-blind, placebo-controlled phase 3 trial aims to determine if Raphamin can speed up symptom resolution, reduce disease severity, and prevent complications requiring antibiotics compared to placebo. The study includes both men and women during the seasonal period of acute respiratory viral infections. Participants are randomly assigned to receive either Raphamin or a placebo following a specific oral dosing schedule for 5 days. On the first day, participants take 8 tablets of Raphamin or placebo one tablet every 30 minutes for the first 2 hours total of 5 tablets, then one tablet three times spaced evenly throughout the day. From day 2 onwards, one tablet is taken three times daily. The study uses an electronic patient diary to record daily symptoms, and face-to-face visits are scheduled on days 1, 4, and 7, with a phone visit on day 14. Throughout the study, participants undergo physical exams, vital sign monitoring, pulse oximetry, and laboratory tests including blood counts and PCR for respiratory viruses. Symptom severity is assessed by the Bronchitis Severity Scale and the Integrative Medicine Outcome Scale. Quality of life is evaluated using the EQ-5D instrument. Safety is monitored through recording adverse events and any use of antibacterial medications or hospitalizations. The total duration of participation includes treatment and follow-up over 14 days.

Age: 18Years - 64YearsAll GendersPhase 3
33 locations
S

Actively Recruiting

Researchers are conducting a multicenter, double-blind, placebo-controlled, randomized clinical trial to study children aged 3 to 12 years with acute respiratory viral infection ARVI. This trial aims to evaluate the safety and effectiveness of Raphamin in treating ARVI symptoms during the seasonal incidence of the illness. Enrollment starts with children aged 6 to 12 years and may expand to include those aged 3 to 12 years based on interim safety and efficacy results. Participants will be randomly assigned to receive either Raphamin or a placebo. Raphamin is given orally as tablets that dissolve in the mouth, with a specific dosing schedule over five days eight tablets on the first day taken at intervals, then one tablet three times daily on days two through five. The placebo group follows the same dosing regimen using placebo tablets. The treatment period lasts five days, followed by monitoring and follow-up visits. During the study, parents or caregivers will record their childs symptoms and body temperature twice daily in an electronic diary, including any use of fever-reducing medications and changes in health. Children will have several visits with healthcare providers on days 1, 5, and 7, plus a phone visit on day 14 for safety and symptom assessment. Laboratory tests and physical exams will be conducted to monitor progress and safety. The primary outcome is the time until ARVI symptoms resolve within 14 days.

Age: 3Years - 12YearsAll GendersPhase 3
35 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a blood purification device called Efferon LPS in patients with acute pancreatitis. The study focuses on reducing the severity of organ dysfunction, which is a major cause of death in severe cases. This approach builds on extracorporeal blood purification methods that help correct imbalances caused by inflammation in intensive care settings. Participants are divided into two groups one receives standard treatment with hemofiltration or hemodiafiltration, and the other receives the same standard treatment combined with the Efferon LPS device. Treatment begins within 48 hours of ICU admission and within 8 hours of enrolling in the study. The device works by filtering harmful substances like endotoxins and cytokines from the blood. During the study, participants will be closely monitored through various assessments including organ function scores, oxygenation, heart function, and length of ICU stay. Researchers will track the duration of vasopressor use, mechanical ventilation, and renal replacement therapy. The study runs until March 2028, with outcome measures collected from 1 to 60 days after treatment starts.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
8 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of a liquid form of Rengalin for treating cough caused by acute viral upper respiratory tract infections in children aged 6 months to 3 years during the epidemic growth of influenza and ARVI. This randomized, double-blind, placebo-controlled trial compares Rengalin with a placebo to determine its effect on cough severity in young children. Participants will be randomly assigned to receive either 5 ml of Rengalin or a placebo orally three times a day for 7 days. The study includes initial screening and consent, followed by treatment and monitoring visits on days 1, 4, and 8, with a phone follow-up on day 14. On day 4, if needed, mucolytic ambroxol may be added while continuing the assigned study treatment. Parents will use an electronic diary to record cough severity twice daily throughout the study. During the study, researchers will assess symptoms, perform physical exams, and conduct laboratory tests including blood and urine analyses in at least half the participants. Safety and treatment adherence are closely monitored through visits and diaries. The main outcome is the percentage of patients responding to treatment by day 3, with secondary outcomes including changes in cough severity by day 7. The total study duration for participants is up to 14 days with ongoing observation.

Age: 6Months - 3YearsAll GendersPhase 3
30 locations
S

Actively Recruiting

Researchers are evaluating the drug 4-MUST to understand its effectiveness, safety, and tolerability in treating patients with chronic cholecystitis and biliary dyskinesia. This study compares different doses of 4-MUST with a placebo to see how well the drug reduces upper abdominal pain and gastrointestinal symptoms. The trial is a phase 2, prospective, randomized, double-blind, placebo-controlled study designed to provide detailed insight into the drugs impact on these digestive conditions. Participants will be randomly assigned to one of four groups. One group receives 1 tablet of 4-MUST 128 mg plus 2 placebo tablets three times daily, another receives 2 tablets of 4-MUST 256 mg plus 1 placebo tablet three times daily, a third group takes 3 tablets of 4-MUST 384 mg three times daily, and the last group receives 3 placebo tablets three times daily. The treatment lasts for 29 days, with doses given three times a day, followed by assessment and monitoring. During the study, participants will undergo regular evaluations including pain measurement using a Visual Analog Scale VAS, gastrointestinal symptom rating via questionnaires, and quality of life assessments with the SF-36 questionnaire. Safety will be monitored through adverse event tracking, physical examinations, vital signs, laboratory tests, and electrocardiograms at multiple time points throughout the 29-day period and up to day 36. These thorough assessments aim to capture the drugs effects and tolerability over the course of treatment.

Age: 18Years - 70YearsAll GendersPhase 2
17 locations
P

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of 4-MUST, 128 mg tablets compared to placebo in adults with chronic cholecystitis and biliary dyskinesia. This phase 3, multicenter, randomized, double-blind study aims to assess how 4-MUST impacts symptoms related to these gallbladder and biliary tract conditions, including pain and gastrointestinal discomfort. Participants are randomly assigned to receive either 4-MUST tablets or placebo. The 4-MUST group takes three 128 mg tablets orally three times a day, 30 minutes before meals, totaling 1152 mg daily. The placebo group takes identical-appearing tablets on the same schedule. Treatment lasts for approximately 29 days, followed by monitoring until day 36. Throughout the study, participants report pain severity in the upper abdomen using a Visual Analog Scale VAS and complete questionnaires about gastrointestinal symptoms and quality of life. Safety is monitored through physical exams, vital signs, laboratory tests, and electrocardiograms at scheduled visits. Researchers track adverse events and treatment tolerability to evaluate the overall impact of 4-MUST compared to placebo during and shortly after treatment.

Age: 18Years - 70YearsAll GendersPhase 3
10 locations

1-10 of 16

1